G-6-PD

Glucose-6-Phosphate Dehydrogenase Deficiency Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzyme deficiency in the pentose phosphate pathway, affecting more than 400 million people worldwide. Clinical manifestations of G6PD deficiency include neonatal jaundice and acute hemolytic anemia arising from oxidative stress on RBCs induced by some medications, an infection, or ingestion of fava beans. However, many individuals with this disorder remain asymptomatic throughout their lives and may not be even aware of it. Drug-induced hemolytic anemia in patients with G6PD deficiency was first described with the antimalaria drug primaquine, but many other drugs are capable of causing hemolytic anemia in these patients Glucose-6-Phosphate Dehydrogenase Deficiency Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzyme deficiency in the pentose phosphate pathway, affecting more than 400 million people worldwide. Clinical manifestations of G6PD deficiency include neonatal jaundice and acute hemolytic anemia arising from oxidative stress on RBCs induced by some medications, an infection, or ingestion of fava beans. However, many individuals with this disorder remain asymptomatic throughout their lives and may not be even aware of it. Drug-induced hemolytic anemia in patients with G6PD deficiency was first described with the antimalaria drug primaquine, but many other drugs are capable of causing hemolytic anemia in these patients

G-6-PD